Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on May 14, 2021 9:04am
80 Views
Post# 33202275

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The other two clinics

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The other two clinics Isn't the hair falling out because taxol, lose in your system, attacks all fast growing cells of which hair is one?  If the docetaxol is directed primarily into the tumor cell and stays there, might it lessen this side effect quite a bit?  Not that it's important, but I'm thinking it could be a signal of the benefit of sortilin as a target and it's internalization function.

juniper88 wrote: I would think that if the Peptide cannot hone in to a sortilin receptor then eventually it would break down and the payload is release into the blood stream, similar to getting just a Taxol IV.  My wife has had 11 cycles of taxol, which is very toxic.  Taxol IV requires premeds, for example IV Benadryl because allergic reactions to Taxol can occur.  Also, the IV is put in on a graduated basis.  So, they start very slow and monitor the patient very closely.  If nothing happens after 15 minutes the nurse increase the IV speed until eventually full speed is reached.

From my understanding, in the TH1902 trial there are no premeds and the IV is done at full speed.  At a higher dose, if the peptide does not work I imagine you would find out rather quickly.

Also, Taxol is one of the Chemos that causes your hair to fall out (not all chemos do, my wife current treatment Carboplatin with Caelyx has allowed her to keep all her hair.)   So, even the patient should be able to notice if TH1902 is working with out any bloodwork.  The hair start falling between the 2nd and 3rd week after the treatment.



<< Previous
Bullboard Posts
Next >>